FDA Extends Review of Pfizer Inc. (JOBS) Osteoporosis Drug

October 22, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

WASHINGTON, Oct 21 (Reuters) - U.S. regulators have extended by three months their review of a proposed osteoporosis drug from Pfizer Inc to study the pill in more depth, a company spokeswoman said on Tuesday.

Twitter
LinkedIn
Facebook
Email
Print

FDA Approvals Regulatory

Pfizer Food and Drug Administration (FDA)